O039 - AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE
ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)
Alvaro Urbano, Arnon Nagler, Gunilla Enblad, et al.
Conclusions: These results demonstrate that clinical CAR T-cell activity is rapidly growing at European centers. Adult patients with NHL now represent the most frequent indication for treatment, because of commercial availability of approved products in this indication. The use of marketed CAR T-cells has increased by 10-fold within 6 months, but still represents a minority of the ongoing activity. The existence of 15 active European academic clinical trials shows that Europe is not just a “CAR buyer” but also a “CAR manufacturer”. We encourage centers to keep registering patients receiving CAR T-cells, both commercial and investigational, in a timely manner, through the specific Med A Form of the EBMT database. This will be crucial to monitor potential improvements in the procedure over time, similar to the achievements made by EBMT in monitoring patients after hematopoietic stem cell transplantation for more than two decades.
More e-posters about CAR-based Cellular Therapy: